Purpose of this Study
Participants will be randomly assigned to receive one of two treatment approaches. One group will receive D-KRd followed by 8 consolidation treatment cycles, while the other group will receive teclistamab followed by 8 consolidation treatment cycles. Researchers will compare the safety and effectiveness of these treatment strategies.
Who Can Participate?
Eligibility
Participants may be able to join if they are 18 to 80 years old and have received little or no prior treatment. They cannot have a history of severe allergic reactions to certain myeloma medicines, serious heart or lung problems caused by prior proteasome inhibitor treatment, or certain related blood disorders. Any significant side effects from previous cancer treatments must have resolved or be stable before joining the study.
Age Range
18-80
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is comparing two consolidation treatments after stem cell transplant in people receiving treatment for multiple myeloma. All participants will receive the same initial treatment and stem cell transplant. After that, one group will receive the usual consolidation therapy, while the other group will receive a different consolidation treatment that includes the study drug teclistamab. Researchers want to learn which approach works better.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Protocol A062401, Quadruplet induction followed by teclistamab consolidation and doublet maintenance in patients with primary plasma cell leukemia: The QUANTUM Trial,(NCT07605416)
Principal Investigator
Cristiana Costa
Chase
Protocol Number
PRO00121142
NCT ID
NCT07605416
Phase
II
Enrollment Status
Pending Open to Enrollment